Table 8.

Outcomes of hip fracture patients by TXA cohort

Characteristics	All 4 doses of TXA	1–3 Doses of TXA	No TXA	P value
Total N	70	50	89	∗	†	‡
Baseline Labs
Admission Hemoglobin (SD)	12.5 (1.61)	12.0 (1.67)	11.5 (1.66)	.217	.184	<.001
Admission Hematocrit % (SD)	38.3 (4.55)	36.9 (4.75)	35.6 (5.02)	.281	.233	.001
Outcomes
Transfusion %	7.1%	22.0%	28.1%	.101	.650	.003
Estimated Blood Loss (SD)	137 (82)	138 (125)	168 (121)	1.000	.276	.201
POD1 Hemoglobin (SD)	10.2 (1.90)	9.9 (1.95)	9.2 (1.58)	.460	.073	.001
Change in POD1 Hemoglobin (SD)	2.29 (1.22)	2.37 (2.00)	2.39 (1.38)	.866	.619	.896
POD2 Hemoglobin (SD)	9.8 (1.71)	9.4 (1.88)	8.6 (1.38)	.405	.017	<.001
Change POD2 Hemoglobin (SD)	2.76 (1.39)	2.54 (1.53)	2.95 (1.42)	.714	.255	.666

This table demonstrates outcome characteristics of hip fracture patients by TXA cohort. The 4 dose TXA cohort had a higher average admission hemoglobin and hematocrit, higher postoperative day 1 and day 2 hemoglobin values, and a shorter hospital length of stay, compared to the cohort that did not receive TXA. There were no differences between the 1 and 3 dose TXA cohort and the other cohorts.

POD = postoperative day.

^∗Denotes the P value derived from a comparison between the group who received all 4 doses of TXA and the group who received between 1 and 3 doses of TXA.

^†Denotes the P value derived from a comparison between the group who received between 1 and 3 doses of TXA and the group who received no TXA.

^‡Denotes the P value derived from a comparison between the group who received all 4 doses of TXA and the group who received no TXA.